Literature DB >> 11149409

Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants.

A Garcia-Lora1, I Algarra, J J Gaforio, F Ruiz-Cabello, F Garrido.   

Abstract

Alteration of MHC class I molecule expression is a widespread mechanism used by tumor cells to evade T cell responses. It has long been proposed that the origin of these MHC class I-negative or -deficient tumor variants is T cell immune selection. However, there are no experimental or clinical data to substantiate this hypothesis, and this issue is currently the subject of debate. Here we report that an H-2 class I-negative fibrosarcoma tumor clone generated MHC class I-negative spontaneous lung metastases in immunocompetent syngeneic BALB/c mice. Interestingly, the same B9 clone generated MHC class I-positive metastatic nodes, under basal conditions, in athymic nu/nu BALB/c mice. This phenomenon was observed in the metastatic nodules generated after a period of in vivo growth but not in the primary tumors growing locally in the footpad. These findings support the hypothesis that the H-2 phenotype of metastatic nodes is influenced by the T cell repertoire of the host, since in the absence of this T cell pressure (i.e., in nude mice) the metastatic nodes 'recovered' H-2 class I expression. In addition, 2 different phenotypes were found when the metastatic nodules obtained from immunocompetent mice were treated with IFN-gamma. One phenotype, present in 83% of the colonies, was characterized by resistance of the Ld molecule to IFN-gamma induction, due to a deletion involving the Ld gene. The second phenotype (17% of the colonies) was similar to the original B9 clone and was characterized by the response of K, D and L class I genes to IFN-gamma. These data provide evidence that the changes in MHC class I expression during tumor development might not be random but could be predictable.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149409     DOI: 10.1002/1097-0215(20010101)91:1<109::aid-ijc1017>3.0.co;2-e

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?

Authors:  A Hamdi; K Cao; L M Poon; F Aung; S Kornblau; M A Fernandez Vina; R E Champlin; S O Ciurea
Journal:  Bone Marrow Transplant       Date:  2015-01-26       Impact factor: 5.483

2.  Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines.

Authors:  T Rodríguez; R Méndez; A Del Campo; N Aptsiauri; J Martín; G Orozco; G Pawelec; D Schadendorf; F Ruiz-Cabello; F Garrido
Journal:  Immunogenetics       Date:  2006-12-20       Impact factor: 2.846

3.  Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.

Authors:  Rafael Carretero; José M Romero; Francisco Ruiz-Cabello; Isabel Maleno; Felix Rodriguez; Francisco M Camacho; Luis M Real; Federico Garrido; Teresa Cabrera
Journal:  Immunogenetics       Date:  2008-06-11       Impact factor: 2.846

4.  Restoration of MHC-I on Tumor Cells by Fhit Transfection Promotes Immune Rejection and Acts as an Individualized Immunotherapeutic Vaccine.

Authors:  María Pulido; Virginia Chamorro; Irene Romero; Ignacio Algarra; Alba S-Montalvo; Antonia Collado; Federico Garrido; Angel M Garcia-Lora
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

Review 5.  Immune Escape after Hematopoietic Stem Cell Transplantation (HSCT): From Mechanisms to Novel Therapies.

Authors:  Paolo Bernasconi; Oscar Borsani
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

Review 6.  Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence.

Authors:  Sean J Judge; William J Murphy; Robert J Canter
Journal:  Front Cell Infect Microbiol       Date:  2020-02-13       Impact factor: 5.293

Review 7.  Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies.

Authors:  Marina Ayres Pereira; Iok In Christine Chio
Journal:  Genes (Basel)       Date:  2019-12-19       Impact factor: 4.096

Review 8.  The urgent need to recover MHC class I in cancers for effective immunotherapy.

Authors:  Federico Garrido; Natalia Aptsiauri; Elien M Doorduijn; Angel M Garcia Lora; Thorbald van Hall
Journal:  Curr Opin Immunol       Date:  2016-01-18       Impact factor: 7.486

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.